Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
1999-08-13
2001-12-11
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C435S325000, C435S366000, C435S368000, C435S369000, C435S371000, C435S455000, C435S456000, C435S357000, C435S363000, C435S352000, C536S023100, C536S023720, C536S024100
Reexamination Certificate
active
06329199
ABSTRACT:
This invention relates to retroviral vectors which are resistant to inactivation by human serum. More particularly, this application relates to retroviral vectors generated from cells which are resistant to lysis by human serum. In another aspect, this invention relates to gene therapy using such vectors.
BACKGROUND OF THE INVENTION
Retroviruses have been and are being used currently as gene delivery vehicles for introducing desired genes into cells, and are being used in a number of gene therapy trials. (Miller,
Nature,
Vol. 375, pgs. 455-460 (1992)). Cornetta, et al.,
Progress in Nucleic Acid Research and Molecular Biolocy,
Vol. 36, pgs. 311-322 (1990) and Cornetta, et al.,
Human Gene Therapy,
Vol. 1, pgs. 15-30 (1990) teach the intravenous infusion into monkeys of an amphotropic murine leukemia retrovirus which includes the human ADA gene. Clinical illness in the monkeys was not observed after administration of the retrovirus. The retroviruses were cleared rapidly from the circulation, and such clearance was mediated in part by complement, which inactivates the virus.
In some trials, direct gene delivery to cells in vivo is being undertaken; for example, the delivery of the Herpes Simplex Virus thymidine kinase gene by recombinant retroviruses to tumors. (Oldfield, et al.,
Human Gene Therapy,
Vol. 4, pgs. 39-69 (1993)). For these trials, murine leukemia virus amphotropic strain (MLV-A) packaging cells, constructed in murine NIH 3T3 cells, are being used to produce recombinant retroviruses.
Murine leukemia viruses produced by NIH3T3 cells, however, can be inactivated rapidly by human serum. Such inactivation is a result of activation of the complement cascade.
The inhibition of infectivity of C-type retroviruses first was demonstrated in reports that four strains of murine leukemia viruses (MLV), and Moloney Sarcoma Virus (MSV) pseudotypes with the envelope specificity of gibbon ape leukemia virus (GALV), or simian sarcoma associated virus (SSAV), were inactivated by fresh, but not heated human serum. (Welsh, et al.,
Nature,
Vol. 257, pgs. 612-614 (1975); Welsh, et al.,
Virology,
Vol. 74, pgs. 432-440 (1976).) Lysis of these viruses, as well as lysis of feline leukemia virus (FeLV), the cat endogenous virus RD114, simian sarcoma associated virus (SSAV), the baboon endogenous virus M28 (BaEV) and the D-type virus Mason-Pfizer monkey virus (MPMV) by human serum was demonstrated by the release of reverse transcriptase activity from virions. (Welsh, et al., 1975; Welsh, et al., 1976; Sherwin, et al.,
Int. J. Cancer,
Vol. 21, pgs. 6-11 (1978).) Complement depleted, or deficient human sera failed to cause viral lysis, and complement consumption was observed when viruses were added to human serum. (Welsh, et al., 1975). Murine leukemia viruses were shown to be lysed following direct, antibody independent triggering of the C1q component to MLV virions. (Cooper, et al.,
J. Exp. Med.,
Vol. 144, pgs. 970-984 (1976).) An isolated 15 Kda virion protein with a pI of 7.5, proposed to be the p15E transmembrane protein, was shown to trigger complement. (Bartholomew, et al.,
J. Exp. Med.,
Vol. 147, pgs. 844-853 (1978).) Retroviruses made by murine cells, however, were found to be inactivated by human serum mainly by recognition of sugar epitopes, Gal (1-3) Gal epitopes, by natural antibodies (Takeuchi, et al., unpublished data).
REFERENCES:
patent: 5470726 (1995-11-01), Miller et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5952225 (1999-09-01), Pensiero et al.
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy” Dec. 1995.*
Welsh et al., Nature, vol. 257, pp. 612-614, Oct. 1975.*
Takeuchi et al., Virology, vol. 186, pp. 792-794, 1992.*
Anderson, Nature, vol. 392, pp. 25-30, Apr. 1998.*
Verma et al., Nature, vol. 389, pp. 239-242, Sep. 1997.
Collins Mary K. L.
Cosset Francois-Loic
Pensiero Michael
Takeuchi Yasuhiro
Weiss Robin A.
Guzo David
Karny Geoffrey M.
LandOfFree
Retroviral vectors produced by producer cell lines resistant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retroviral vectors produced by producer cell lines resistant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral vectors produced by producer cell lines resistant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2580202